Innate Pharma saw the highest growth of 99% in patent filings in October and 49% in grants in November in Q4 2023. Compared to Q3 2023, Q4 2023 saw an increase in patent filings by 99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Innate Pharma‘s patent filings and grants. Buy the databook here.
Innate Pharma has been focused on protecting inventions in United States(US) with three publications in Q4 2023
The United States(US) Patent Office dominates the patent filings and grants with nearly 33% filings and 33% grants. The United States(US), European Patent Office(EPO), Australia(AU), and China(CN) patent Office are among the top ten patent offices where Innate Pharma is filings its patents. Among the top granted patent authorities, Innate Pharma has 33% of its grants in United States(US), 33% in China(CN) and 33% in Spain(ES).
Patents related to rare diseases lead Innate Pharma's portfolio
See Also:
Innate Pharma has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and 100% of patents were granted in Q4 2023.
Breast cancer related patents lead Innate Pharma portfolio followed by cutaneous lupus erythematosus, and solid tumor
Innate Pharma has highest number of patents in breast cancer followed by cutaneous lupus erythematosus, solid tumor, melanoma, and head and neck cancer.
For comprehensive analysis of Innate Pharma's filings and grants, buy the databook here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.